When it comes to drugs, one of the most common questions patients ask is, Are generic drugs as effective as branded ones? Despite decades of clinical evidence and strict global regulations, myths about generic drugs continue to circulate, often creating unnecessary hesitation and confusion. In reality, generic drugs play a vital role in making healthcare…

Serialization was once a regulatory checkbox. Today, it’s the backbone of compliant, efficient, and transparent clinical trial supply management. Yet, many pharmaceutical companies continue to rely on legacy serialization systems that were built more than a decade ago. These systems can’t keep up with modern compliance demands, data interoperability, or global supply complexity. What was once…

This article, authored by our Founder Salim Shaikh in International Clinical Trial Magazine, explores how technology partnerships are reshaping clinical trials and building smarter, patient-centric supply chains. Clinical trials are evolving faster than ever before. They are driven by innovative technology partnerships that redefine how research reaches patients. From overcoming geographic barriers to improving patient…

Generic drugs are essential to global healthcare, making treatments more affordable and accessible to the audience. They account for over 90% of prescriptions in the U.S. market and about two-thirds in the European market. However, developing a generic isn’t just about copying a brand drug; it requires strict bioequivalence (BE) studies to prove the generic…

Ever wondered why some clinical trials get delayed even before patient recruitment begins? One of the biggest culprits is inefficient comparator drug sourcing. Comparator sourcing seems quite straightforward, but it is often riddled with misconceptions. It's very natural to believe that it’s just about “buying the drug,” but in reality, it is a complex yet…

Selecting the right clinical trial supplier is a crucial step that can make or break the success of your clinical research. In a competitive landscape with over 50,000 pharma and biotech firms globally, choosing a reliable partner for clinical trial supplies has never been more critical. This comprehensive guide sheds light on factors, processes, and…

When filing an NCE-1 application, being the first applicant to do so is not just a badge of honor; it also gives a strategic edge. The Para IV filing offers exclusive opportunities to dominate the market before competitors enter the scene. Despite this lucrative benefit, common myths persist, clouding judgment, delaying action, and costing companies…

2028 is going to be a landmark year in the pharmaceutical industry. Several blockbuster drugs, each with billion-dollar sales projections, will lose patent exclusivity, opening the door for Para IV filings. For generic and biosimilar manufacturers, this represents a great opportunity. With the right data, the right timing, and tools like NCE Grid to track…

The Promise of Healing Without Medicines Imagine a situation wherein, instead of treating diseases with medications for the rest of your life, your body could actually repair itself. That's the exciting promise of stem cell therapy, also popularly known as regenerative medicine. Stem cell therapy isn't just about treating disease—it's about giving your body the…

Clinical trial supply management (CTSM) involves all the processes, such as planning, forecasting, procurement, manufacturing, storage, and distribution of clinical trial supplies in an efficient manner. This ensures that the appropriate clinical trial supplies reach clinical trial participants at the right time and in accurate condition. CTSM is a crucial part of running clinical trials…